Palisade Bio (PALI)

Company Profile

Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology with human disease to advance novel therapeutics that target and improve the integrity of the intestinal barrier.

Company profile

Ticker

PALI

Exchange

NASDAQ

Website

senecabio.com/

CEO

Kenneth Carter

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...

Former names

Neuralstem, Inc., Seneca Biopharma, Inc.

SEC CIK

0001357459

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Leading Biosciences, Inc. • Suzhou Neuralstem Biopharmaceutical Co., Ltd. ...

IRS number

522007292

PALI stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

14 Sep 23

8-K

Entry into a Material Definitive Agreement

11 Sep 23

8-K

Entry into a Material Definitive Agreement

11 Sep 23

424B5

Prospectus supplement for primary offering

11 Sep 23

8-K

Entry into a Material Definitive Agreement

10 Aug 23

Entry into a Material Definitive Agreement

Notice of effectiveness

28 Apr 23

424B3

Prospectus supplement

27 Apr 23

Latest ownership filings

View all

Robert J. Trenschel

15 Sep 23

SC 13G

L1 Capital Global Opportunities Master Fund, Ltd.

15 Sep 23

SC 13G

Lind Global Fund II LP

15 Sep 23

John David Finley

14 Sep 23

Mitchell Lawrence Jones

Financial summary

Financial statements Chart PALI financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	16.43 mm	16.43 mm	16.43 mm	16.43 mm	16.43 mm	16.43 mm
Cash burn (monthly)	(no burn)	(no burn)	1.20 mm	1.20 mm	733.00 k	1.01 mm
Cash used (since last report)	n/a	n/a	3.39 mm	3.38 mm	2.07 mm	2.84 mm
Cash remaining	n/a	n/a	13.04 mm	13.04 mm	14.36 mm	13.59 mm
Runway (months of cash)	n/a	n/a	10.8	10.9	19.6	13.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

PALI institutional ownership history Ownership history

37.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	13	12	+8.3%
Opened positions	4	2	+100.0%
Closed positions	3	6	-50.0%
Increased positions	3	3	–
Reduced positions	2	2	–

13F shares	Current	Prev Q	Change
Total value	231.70 mm	26.33 mm	+779.9%
Total shares	2.54 mm	2.42 mm	+5.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Regional Medical Center Yuma	2.25 mm	$5.55 mm	0.0%
Intracoastal Capital	131.09 k	$0.00	0.0%
Geode Capital Management	42.25 k	$71.82 mm	NEW
Vanguard	35.57 k	$60.47 mm	NEW
Lind Global Fund II	30.99 k	$0.00	0.0%
BAC Bank Of America	30.00 k	$51.00 mm	NEW
STT State Street	22.46 k	$38.19 mm	NEW
MS Morgan Stanley	2.04 k	$3.47 mm	-36.8%
WFC Wells Fargo & Co.	372.00	$633.00 k	+11.0%
Advisor	221.00	$376.00 k	+82.6%

Largest transactions	Shares	Bought/sold	Change
Geode Capital Management	42.25 k	+42.25 k	NEW
Vanguard	35.57 k	+35.57 k	NEW
BAC Bank Of America	30.00 k	+30.00 k	NEW
STT State Street	22.46 k	+22.46 k	NEW
Tower Research Capital	0.00	-2.48 k	EXIT
UBS UBS Group AG - Registered Shares	108.00	-1.23 k	-92.0%
MS Morgan Stanley	2.04 k	-1.19 k	-36.8%
JPM JPMorgan Chase & Co.	0.00	-626.00	EXIT
Orion Capital Management	0.00	-299.00	EXIT
Advisor	221.00	+100.00	+82.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PALI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Sep 23	Robert J. Trenschel	Common Stock, par value $0.01	Sell	Dispose S	No	No	0.64	300	192.00	0
13 Sep 23	John David Finley	Common Stock, par value $0.01	Buy	Acquire P	No	No	0.655	15,000	9.83 k	28,394
12 Sep 23	John David Finley	Common Stock, par value $0.01	Payment of exercise	Dispose F	No	No	0.655	1,792	1.17 k	13,394
11 Sep 23	John David Finley	Common Stock, par value $0.01	Option exercise	Acquire M	No	No	0	5,558	0.00	15,186
11 Sep 23	John David Finley	RSU Common Stock	Option exercise	Dispose M	No	No	0	5,558	0.00	61,142
11 Aug 23	John David Finley	Common Stock, par value $0.01	Payment of exercise	Dispose F	No	No	0.7	1,040	728.00	9,628
6 Aug 23	John David Finley	Common Stock, par value $0.01	Option exercise	Acquire M	No	No	0	3,475	0.00	11,057
6 Aug 23	John David Finley	RSU Common Stock	Option exercise	Dispose M	No	No	0	3,475	0.00	34,750